Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

BACKGROUND: Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-in...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Griffiths, Paul D, Stanton, Anna, McCarrell, Erin, Smith, Colette, Osman, Mohamed, Harber, Mark, Davenport, Andrew, Jones, Gareth, Wheeler, David C, O'Beirne, James, Thorburn, Douglas, Patch, David, Atkinson, Claire E, Pichon, Sylvie, Sweny, Paul, Lanzman, Marisa, Woodford, Elizabeth, Rothwell, Emily, Old, Natasha, Kinyanjui, Ruth, Haque, Tanzina, Atabani, Sowsan, Luck, Suzanne, Prideaux, Steven, Milne, Richard SB, Emery, Vincent C, Burroughs, Andrew K
Формат: Artigo
Язык:Inglês
Опубликовано: Lancet Publishing Group 2011
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3075549/
https://ncbi.nlm.nih.gov/pubmed/21481708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60136-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы